Revolution Medicines (RVMD) Soars on Pancreatic Cancer Drug Success and Analyst Upgrades

Font: Financial Modeling Prep  • Apr 13, 2026

• Revolution Medicines' experimental drug, daraxonrasib, significantly extended survival for pancreatic cancer patients in a Phase 3 trial, nearly doubling the typical survival length.
• Following these positive clinical trial results, leading analyst firms, including Oppenheimer, Leerink, and Guggenheim, raised their price targets for RVMD, signaling strong confidence in the biotech company's future prospects.
• The positive news propelled RVMD's stock price to a record high, with Oppenheimer maintaining an "Outperform" rating and a target price well above the current trading level, suggesting further growth potential for the cancer therapy innovator.

Revolution Medicines (NASDAQ:RVMD) is a leading biotechnology company that focuses on developing new cancer therapies. The company is currently gaining attention for its groundbreaking work on a pancreatic cancer treatment. Its main efforts are centered on creating targeted drugs that can help patients with specific types of cancer, driving innovation in the pharmaceutical sector.

On April 13, 2026, analyst firm Oppenheimer increased its price target for RVMD. A price target is an analyst's estimate of a stock's future value. Oppenheimer raised its target to $165 from $150, showing increased confidence in the company's future performance. This decision came after the company announced positive clinical trial results for its promising cancer drug.

The positive news centers on daraxonrasib, the company's experimental pill for pancreatic cancer. The drug successfully completed a late-stage Phase 3 trial. As highlighted by Invezz, the trial showed that the drug nearly doubled the typical survival length for patients compared to standard chemotherapy, from 6.7 months to 13.2 months. This significant improvement underscores the potential of this novel cancer therapy.

Following the news, the RVMD stock price increased sharply by over 35%, reaching a record high of $135.81 during the trading session. The successful trial results also prompted other analyst firms to react. Leerink and Guggenheim raised their price targets to $147 and $174, respectively, joining Oppenheimer in their positive outlook on the biotech stock.

Oppenheimer maintained its "Outperform" rating on the stock. This rating suggests the analyst believes RVMD will perform better than the overall stock market. At the time of the rating, the stock was trading at $133.08, which is below Oppenheimer's new target of $165, indicating potential for further upside in Revolution Medicines' valuation.